Zensar Technologies Board Approves Merger of US Subsidiaries

Zensar Technologies Limited's Board of Directors has granted in-principle approval for the merger of its US-based step-down subsidiaries, Bridgeview Life Sciences LLC and M3BI LLC, into Zensar Technologies Inc., USA. This strategic move aims to achieve greater business synergies, enhance operational efficiencies, and enable unified control of operations. The merger is expected to result in the cessation of Bridgeview Life Sciences LLC and M3BI LLC as separate entities. The transaction does not involve cash consideration or a change in Zensar Technologies Limited's shareholding pattern. Financial details for the merging entities as of March 31, 2026, show Bridgeview Life Sciences LLC with a net worth of $0.4 million and turnover of $4.74 million, and M3BI LLC with a net worth of $9.32 million and turnover of $46.8 million. Zensar Technologies Inc. reported a net worth of $74.66 million and turnover of $326.96 million.